Collaboration and License Agreements - Lilly (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Feb. 28, 2022
Collaborative Agreements disclosures
Aggregate amount of transaction price allocated to remaining performance obligations	$ 44,600		$ 44,600
Revenue from contract with customer	83,153	$ 14,162	133,022	$ 52,240
Amount of obligation included in long-term deferred revenue	30,217		30,217		$ 36,355
Lilly
Collaborative Agreements disclosures
License agreement upfront payment receivable						$ 13,000
License agreement additional payment receivable						19,500
License agreement, target selection fees and development, regulatory and commercial milestone payments receivable						$ 1,700,000
Lilly | Upfront payment
Collaborative Agreements disclosures
License agreement upfront payment receivable	13,000		13,000
Lilly | Initial targets
Collaborative Agreements disclosures
Revenue from contract with customer				$ 9,200	18,400
Lilly | Additional targets
Collaborative Agreements disclosures
License agreement additional payment receivable					$ 13,000
Lilly | Material rights to obtain licenses to replacement targets
Collaborative Agreements disclosures
Amount of obligation included in long-term deferred revenue	$ 7,600		$ 7,600